The find of COVID-19 vaccine: Challenges and opportunities

ElBagoury, Marwan; Tolba, Mahmoud M; Nasser, Hebatallah A.; Jabbar, Abdul; Tolba, Mahmoud M.; Aktham, Yahia; Hutchinson, Amy

doi:10.1016/j.jiph.2020.12.025

Cited by 57 publications

(40 citation statements)

References 249 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After that, in January 2020, a novel coronavirus causing pneumonia was confirmed by Chinese under the name of 2019 nCoV. World Health Organization (WHO), Chinese authorities and other partners have worked to understanding about properties, sources, prevention of virus spread, and treatments [113]. However, COVID-19 pandemic is spreading all over the world unprecedentedly that impacts on global economy individual and community health seriously.…”

Section: Lipid-based Nanoparticles For Vaccinesmentioning

confidence: 99%

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

COVID-19 vaccines have been developed with unprecedented speed which would not have been possible without decades of fundamental research on delivery nanotechnology. Lipid-based nanoparticles have played a pivotal role in the successes of COVID-19 vaccines and many other nanomedicines, such as Doxil® and Onpattro®, and have therefore been considered as the frontrunner in nanoscale drug delivery systems. In this review, we aim to highlight the progress in the development of these lipid nanoparticles for various applications, ranging from cancer nanomedicines to COVID-19 vaccines. The lipid-based nanoparticles discussed in this review are liposomes, niosomes, transfersomes, solid lipid nanoparticles, and nanostructured lipid carriers. We particularly focus on the innovations that have obtained regulatory approval or that are in clinical trials. We also discuss the physicochemical properties required for specific applications, highlight the differences in requirements for the delivery of different cargos, and introduce current challenges that need further development. This review serves as a useful guideline for designing new lipid nanoparticles for both preventative and therapeutic vaccines including immunotherapies.

show abstract

Section: Lipid-based Nanoparticles For Vaccinesmentioning

confidence: 99%

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Though there are lots of barriers toward imposing the vaccination drive such as false beliefs and misconceptions, technological tools like online surveys conducted by Facebook have the potential to reach over two billion people around the world. It has partnerships with numerous academic and nonprofit institutions to offer humanitarian efforts and tackle challenges about the COVID-19 vaccination drive [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Role of Information Technology in COVID-19 Vaccination Drive: An Analysis of the COVID-19 Global Beliefs, Behaviors, and Norms Survey

Talukdar¹,

Stojkovski²,

Suárez³

et al. 2021

Cureus

View full text Add to dashboard Cite

With the onset of the COVID-19 pandemic, information technology has played a critical role in healthcare. A broad spectrum of information technology tools and applications played an essential role to create awareness of the COVID-19 vaccination drive and its health benefits. Research conducted by Massachusetts Institute of Technology (MIT) in collaboration with information technology platforms like Facebook with inputs from World Health Organization (WHO), John Hopkins University (JHU), and Global Outbreak Alert and Response Network (GOARN) shows that 65.06% of people all over the globe are willing to get vaccinated. Vaccine acceptance depends upon social norms and human behavior. These organizations conducted the global survey in over 60 countries with a sample size of 437,236 responses. The international survey was organized using a pre-registered randomized experiment demonstrating the role of technology in reaching out to people based in diverse communities and evaluating their beliefs, behavior, and social norms. The study shows that vaccine acceptance can vary due to descriptive norms. All the respondents in the study were adults with access to the internet. Moreover, a large proportion of the population thinks that the COVID-19 pandemic is a viable threat to the community and preventive measures need to be taken including vaccination drives to eradicate the menace. The survey consisted of five blocks involving questions related to healthcare, demographics, vaccines, knowledge, and information exposure. Sampling and weighting were done using a pool of 3,000 respondents over two weeks, and weights were provided per respondent to represent the target population as a whole. It reduces the representation error and minimizes non-response biases.

show abstract

“…According to the WHO by late 2020 a total of 233 vaccines were in development and 61 clinical trials had been conducted using a variety of vaccine technologies [14,15]. However, further development of a safe and effective COVID-19 vaccine is fraught with challenges and opportunities [16]. As of March 1, 2021, China, the United States, Israel, the United Kingdom, Russia, Germany, and other countries have approved mass vaccination plans of their own vaccines in their own populations.…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of COVID-19 vaccine: A protocol of systematic review and meta-analysis

Xue

Deng

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The coronavirus disease 2019 (COVID-19) is one of the most wide-spread and threatening infectious diseases in human history. Experts in the field of medicine and biology are working to develop methods to treat and prevent COVID-19. Currently, COVID-19 is predominantly treated with symptomatic therapy and there is still a lack of effective antiviral therapy. Therefore, the prevention and control of novel coronavirus is primarily focused on vaccine development. Several vaccines have been developed, but their relative efficacy and safety have not been proven. Therefore, the aim of this study is to investigate the efficacy and safety of COVID-19 vaccines.Methods and analysis: The electronic databases we will use to retrieve information include PubMed, The Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Database and Weipu Electronics. The retrieval period is from the establishment of the database to March 2021. All randomized controlled trials in humans vaccinated with COVID-19 were collected, and data were independently selected and extracted according to predesigned inclusion/exclusion criteria. Full-text screening, data extraction and quality assessment were conducted independently by two reviewers. Two additional investigators will conduct report quality, risk of bias, sensitivity analysis and subgroup analysis to ensure the reliability of our study results. The software RevMan 5.3 was used for statistical analysis. Systematic review and meta-analyses will be conducted to evaluate the pooled evidence of efficacy and safety of the COVID-19 vaccines.Result: This study will evaluate the efficacy and safety of the COVID-19 vaccines.Conclusion: The conclusions of this study will provide an evidence-based analysis of the safety and efficacy of COVID-19 vaccines.Systematic review registration: PROSPERO CRD42021242581

show abstract

The find of COVID-19 vaccine: Challenges and opportunities

Cited by 57 publications

References 249 publications

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Role of Information Technology in COVID-19 Vaccination Drive: An Analysis of the COVID-19 Global Beliefs, Behaviors, and Norms Survey

The efficacy and safety of COVID-19 vaccine: A protocol of systematic review and meta-analysis

Contact Info

Product

Resources

About